Accordingly, Hsu et al. [83] reported that CTNNB1 mutations were associated with non-HBV-related HCC, lower stage and good prognosis, suggesting that the mechanisms of β-catenin mutations are different between HBV-related and non-HBV-related HCCs and that β-catenin mutation may be a favorable prognostic marker. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.